Watch NBIX. Know when insiders buy.
One email the day a filing lands. Free.
NBIX
NEUROCRINE BIOSCIENCES INC
141.31
−0.69 −0.49%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
26
FLAG · insiders 27, shorts 25
Insiders, 90 days
−$826K
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
3 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $14.4BP/E 20.7DIV YIELD —FCF YIELD 6.06%REV TTM $3.4B +34.4%NET INCOME $705.5M +102.6%NET CASH —52W 123.10 – 185.50SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $959M | +39.5% | — | $151.5M | $144.4M | +34.3% | 1.39 | $136.4M | $7.8M | $128.6M | Jul 31 |
| Q1 2026 · Mar 31 | $814.5M | +42.2% | 98.3% | $193.4M | $197.9M | +2405.1% | 1.91 | $145.8M | $9.1M | $136.7M | May 5 |
| Q4 2025 · Dec 31derived | $805.5M | +28.3% | 97.8% | $210.9M | $153.7M | +49.1% | 1.48 | $388.4M | −$2.4M | $390.8M | Feb 11 |
| Q3 2025 · Sep 30 | $794.9M | +27.8% | 98.2% | $239M | $209.5M | +61.4% | 2.04 | $227.5M | $13.2M | $214.3M | Oct 28 |
| Q2 2025 · Jun 30 | $687.5M | +16.5% | 98.4% | $145.6M | $107.5M | +65.4% | 1.06 | $102M | $12.5M | $89.5M | Jul 31 |
| Q1 2025 · Mar 31 | $572.6M | +11.1% | 98.4% | $23.6M | $7.9M | −81.8% | 0.08 | $64.8M | $10.7M | $54.1M | May 5 |
| Q4 2024 · Dec 31derived | $627.7M | +21.8% | 98.5% | $142M | $103.1M | −30.2% | 1.00 | $242.5M | $7.3M | $235.2M | Feb 11 |
| Q3 2024 · Sep 30 | $622.1M | +24.7% | 98.7% | $183.8M | $129.8M | +56.2% | 1.24 | $158M | $8.1M | $149.9M | Oct 28 |
| Q2 2024 · Jun 30 | $590.2M | — | 98.4% | $145.4M | $65M | — | 0.63 | $64.6M | $11.6M | $53M | Jul 30 |
| Q1 2024 · Mar 31 | $515.3M | — | 98.5% | $99.3M | $43.4M | — | 0.42 | $130.3M | $11.2M | $119.1M | May 5 |
| Q4 2023 · Dec 31derived | $515.2M | — | 98.4% | $150.3M | $147.7M | — | 1.46 | $123.5M | $5.4M | $118.1M | Feb 11 |
| Q3 2023 · Sep 30 | $498.8M | — | 97.8% | $141.2M | $83.1M | — | 0.82 | $212M | $7.6M | $204.4M | Oct 30 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2.9B | 98.2% | $619.1M | $478.6M | 16.7% | 4.67 | $782.7M | $34M | $748.7M | $167.7M | — |
| FY2024 · to Dec 31 | $2.4B | 98.6% | $570.5M | $341.3M | 14.5% | 3.29 | $595.4M | $38.2M | $557.2M | $300M | — |
| FY2023 · to Dec 31 | $1.9B | 97.9% | $250.9M | $249.7M | 13.2% | 2.47 | $389.9M | $28.3M | $361.6M | $0 | — |
| FY2022 · to Dec 31 | $1.5B | 98.4% | $249M | $154.5M | 10.4% | 1.56 | $339.4M | $16.5M | $322.9M | $0 | — |
| FY2021 · to Dec 31 | $1.1B | 98.7% | $102.5M | $89.6M | 7.9% | 0.92 | $256.5M | $23.4M | $233.1M | — | — |
| FY2020 · to Dec 31 | $1B | 99.0% | $163M | $407.3M | 38.9% | 4.16 | $228.5M | $10.9M | $217.6M | — | — |
Every number comes from NEUROCRINE BIOSCIENCES INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.